Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Trial Profile

A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs RT 001 (Primary)
  • Indications Neuroaxonal dystrophies
  • Focus Registrational; Therapeutic Use
  • Sponsors Retrotope
  • Most Recent Events

    • 13 Dec 2018 According to a Retrotope media release, first two trial sites, Atlantic Healths Goryeb Childrens Hospital in Morristown, NJ, and the UCSF Benioff Childrens Hospital San Francisco are now evaluating and enrolling patients for the trial.
    • 13 Dec 2018 According to a Retrotope media release, company has begun enrollment of the first patients and has started dosing of infants.
    • 06 Nov 2018 Planned End Date changed from 31 Dec 2019 to 31 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top